BACKGROUND: Urinary incontinence is a common short-term complication of radical prostatectomy (RP). Little is known about the long-term impact of RP on continence. OBJECTIVE: To elucidate the long-term progression of continence after RP. DESIGN, SETTING, AND PARTICIPANTS: From October 2000 through September 2012, 1788 men undergoing open RP for clinically localized prostate cancer by a single surgeon at an urban tertiary care center prospectively signed consent to be followed before RP and at 3, 6, 12, 24, 96, and 120 mo after RP. A consecutive sampling method was used and all men were included in this study. INTERVENTION: Men underwent open RP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Regression models controlled for preoperative University of California, Los Angeles-Prostate Cancer Index urinary function score (UCLA-PCI-UFS), age, prostate-specific antigen level, Gleason score, stage, nerve-sparing status, race, and marital status were used to evaluate the association of time since RP with two dependent variables: UCLA-PCI-UFS and continence status. RESULTS AND LIMITATION: The mean UCLA-PCI-UFS declined between 2 yr and 8 yr (83.8 vs 81.8; p=0.007) and marginally between 8 yr and 10 yr (81.8 vs 79.6; p=0.036) after RP, whereas continence rate did not significantly change during these intervals. Men ≥ 60 yr old experienced a decline in mean UCLA-PCI-UFS between 2 yr and 8 yr (p=0.002) and a marginal decline in continence rate between 2 yr and 10 yr (p=0.047), whereas these variables did not change significantly in men <60 yr old. These outcomes are for an experienced surgeon, so caution should be exercised in generalizing these results. CONCLUSIONS: Between 2 yr and 10 yr after RP, there were slight decreases in mean UCLA-PCI-UFS and continence rates in this study. Men aged <60 yr had better long-term outcomes. These results provide realistic long-term continence expectations for men undergoing RP.
BACKGROUND: Urinary incontinence is a common short-term complication of radical prostatectomy (RP). Little is known about the long-term impact of RP on continence. OBJECTIVE: To elucidate the long-term progression of continence after RP. DESIGN, SETTING, AND PARTICIPANTS: From October 2000 through September 2012, 1788 men undergoing open RP for clinically localized prostate cancer by a single surgeon at an urban tertiary care center prospectively signed consent to be followed before RP and at 3, 6, 12, 24, 96, and 120 mo after RP. A consecutive sampling method was used and all men were included in this study. INTERVENTION: Men underwent open RP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Regression models controlled for preoperative University of California, Los Angeles-Prostate Cancer Index urinary function score (UCLA-PCI-UFS), age, prostate-specific antigen level, Gleason score, stage, nerve-sparing status, race, and marital status were used to evaluate the association of time since RP with two dependent variables: UCLA-PCI-UFS and continence status. RESULTS AND LIMITATION: The mean UCLA-PCI-UFS declined between 2 yr and 8 yr (83.8 vs 81.8; p=0.007) and marginally between 8 yr and 10 yr (81.8 vs 79.6; p=0.036) after RP, whereas continence rate did not significantly change during these intervals. Men ≥ 60 yr old experienced a decline in mean UCLA-PCI-UFS between 2 yr and 8 yr (p=0.002) and a marginal decline in continence rate between 2 yr and 10 yr (p=0.047), whereas these variables did not change significantly in men <60 yr old. These outcomes are for an experienced surgeon, so caution should be exercised in generalizing these results. CONCLUSIONS: Between 2 yr and 10 yr after RP, there were slight decreases in mean UCLA-PCI-UFS and continence rates in this study. Men aged <60 yr had better long-term outcomes. These results provide realistic long-term continence expectations for men undergoing RP.
Authors: David C Miller; Martin G Sanda; Rodney L Dunn; James E Montie; Hector Pimentel; Howard M Sandler; William P McLaughlin; John T Wei Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: David F Penson; Dale McLerran; Ziding Feng; Lin Li; Peter C Albertsen; Frank D Gilliland; Ann Hamilton; Richard M Hoffman; Robert A Stephenson; Arnold L Potosky; Janet L Stanford Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Francesco Montorsi; Timothy G Wilson; Raymond C Rosen; Thomas E Ahlering; Walter Artibani; Peter R Carroll; Anthony Costello; James A Eastham; Vincenzo Ficarra; Giorgio Guazzoni; Mani Menon; Giacomo Novara; Vipul R Patel; Jens-Uwe Stolzenburg; Henk Van der Poel; Hein Van Poppel; Alexandre Mottrie Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: Shilajit D Kundu; Kimberly A Roehl; Scott E Eggener; Jo Ann V Antenor; Misop Han; William J Catalona Journal: J Urol Date: 2004-12 Impact factor: 7.450
Authors: Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Justin K Lee; Melissa Assel; Alan E Thong; Daniel D Sjoberg; John P Mulhall; Jaspreet Sandhu; Andrew J Vickers; Behfar Ehdaie Journal: Eur Urol Date: 2015-08-17 Impact factor: 20.096
Authors: Jerome Gnanaraj; Shobana Balakrishnan; Zarish Umar; Emmanuel S Antonarakis; Christian P Pavlovich; Scott M Wright; Waseem Khaliq Journal: Med Oncol Date: 2016-06-20 Impact factor: 3.064
Authors: F Abdollah; D Dalela; A Sood; J Sammon; R Cho; L Nocera; M Diaz; W Jeong; J O Peabody; N Fossati; G Gandaglia; A Briganti; F Montorsi; M Menon Journal: Prostate Cancer Prostatic Dis Date: 2017-05-02 Impact factor: 5.554